Giancarlo Comi, MD
Treatment of Progressive MS: Why, Who, When, How
Prof. Ralf Gold
SPECIAL REPORT: Expert Opinion on New MS Drug Approval
Now Approved in Europe: First Oral Short-Course Treatment for Highly Active Relapsing MS
Now Approved in Europe: First Oral Short-Course Treatment for Highly Active R...
Cladribine Receives Positive CHMP Opinion for Relapsing MS Treatment
Jiwon Oh, MD
The Diagnostic Challenges of Spinal Cord Lesions in MS
Reducing the Burden of MS Treatment
Therapeutic Mechanism of Action (MOAs) in MS: Targeting T- and B-cells to Reset the Immune System
Therapeutic Mechanism of Action (MOAs) in MS: Targeting T- and B-cells to Res...
Benefit/Risk Strategies in Selecting Therapeutic Solutions for MS
Optimizing MS Treatment Options
Establishing Partnerships to Optimize Patient Outcomes
Immunologic Effects on Metabolic Syndrome and MS
Highlights from the MAGNIMS Consensus Guidelines
Current and Future MS Treatment Options
Determining an MS Patient's Long-Term Prognosis
Emerging MRI Techniques in MS Patients
The Value of Biomarkers in MS Patients
Stay current with the best on medical education
We’re glad to see you’re enjoying Global Neurology Academy…but how about a more personalized experience?
Press cancel to remain on Global Neurology Academy. Press the link below or the continue button to keep going.